27 Jan 2021 by admin in UncategorizedComments Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
26 Jan 2021 by admin in UncategorizedComments Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
14 Jan 2021 by admin in UncategorizedComments Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
11 Jan 2021 by admin in UncategorizedComments Syros Announces Strategic Priorities and Expected Milestones
07 Jan 2021 by admin in UncategorizedComments KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES
10 Dec 2020 by admin in UncategorizedComments Crescendo Biologics Expands its Ongoing Collaboration with Takeda
07 Dec 2020 by admin in UncategorizedComments Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma
01 Dec 2020 by admin in UncategorizedComments Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
20 Nov 2020 by admin in UncategorizedComments Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company， Announces Closing of $50 Million Series A Financing
12 Nov 2020 by admin in UncategorizedComments Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
06 Nov 2020 by admin in UncategorizedComments Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China
05 Nov 2020 by admin in UncategorizedComments Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
29 Oct 2020 by admin in UncategorizedComments Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors
29 Oct 2020 by admin in UncategorizedComments Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant)
24 Oct 2020 by admin in UncategorizedComments Syros Presents Initial Data from Phase 1Clinical Trial of SY-5609
21 Oct 2020 by admin in UncategorizedComments SAM WHITING, M.D., PH.D., joins TEMPEST as executive vice president and chief medical officer
20 Oct 2020 by admin in UncategorizedComments Design Therapeutics Appoints Industry Veteran, Dr. João Siffert, as Chief Executive Officer
14 Sep 2020 by admin in UncategorizedComments NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
09 Sep 2020 by admin in UncategorizedComments Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
24 Aug 2020 by admin in UncategorizedComments Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002
06 Aug 2020 by admin in UncategorizedComments Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
30 Jul 2020 by admin in UncategorizedComments Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
30 Jul 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Result
28 Jul 2020 by admin in UncategorizedComments resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
22 Jun 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 May 2020 by admin in UncategorizedComments resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 May 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
